Access the full text.
Sign up today, get DeepDyve free for 14 days.
A Stewart, J Steiner, G Mellows, B Laguda, D Norris, P Bevan (2000)
Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administrationClin Cancer Res, 6
M Wartenberg, FC Ling, M Schallenberg, AT Baumer, K Petrat, J Hescheler, H Sauer (2001)
Down-regulation of intrinsic P-glycoprotein expression in multicellular prostate tumor spheroids by reactive oxygen speciesJ Biol Chem, 276
B Sarkadi, EM Price, RC Boucher, UA German, GA Scarborough (1992)
Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug stimulated membrane ATPaseJ Biol Chem, 267
S Anuchapreeda, P Leechanachai, M Smith, SV Ambudkar, P Limtrakul (2002)
Modulation of P-glycoprotein expression and function by curcumin in multidrug resistant human KB cellsBiochem Pharmacol, 64
A Mookerjee, J Mookerjee Basu, P Dutta, S Majumder, S Bhattacharyya, J Biswas, S Pal, P Mukherjee, S Raha, RN Baral, T Das, T Efferth, G Sa, S Roy, SK Choudhuri (2006)
Overcoming drug-resistant cancer by a newly developed copper chelate through host-protective cytokine-mediated apoptosisClin Cancer Res, 12
FJ Sharom, X Yu, P Lu, P Liu, JW Chu, K Szabo, M Muller, CD Hose, A Monks, A Varadi, J Seprodi, B Sarkadi (1999)
Interaction of the P-glycoprotein multidrug transporter (MDR1) with high affinity peptide chemosensitizers in isolated membranes, reconstituted systems and intact cellsBiochem Pharmacol, 3
P Brost, RO Elferink (2002)
Mammalian ABC transporters in health and diseaseAnnu Rev Biochem, 71
SJ Currier, SE Kane, MC Willingham, CO Cardarelli, I Pastan, MM Gottesman (1992)
Identification of residues in the first cytoplasmic loop of P-glycoprotein involved in the function of chimeric human MDR1-MDR2 transportersJ Biol Chem, 267
CM Kruijtzer, JH Beijnen, H Rosing, WW Bokkel Huinink, M Schot, RC Jewell (2002)
Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918J Clin Oncol, 20
S Chatterjee, A Mookerjee, J Mookerjee Basu, P Chakroborty, A Ganguly, A Adhikary, D Mukhopadhyay, S Ganguli, R Banerjee, A Mohammad, J Biswas, PK Das, G Sa, M Chatterjee, T Das, SK Choudhuri (2009)
A novel copper chelate modulates tumor associated macrophages to promote anti-tumor response of T cellsPLoS One, 4
R Krishna, LD Mayer (2000)
Multidrug resistance (MDR) in cancer mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugsEur J Pharm Sci, 11
S Dey, M Ramachandra, I Pastan, MM Gottesman, SV Ambudkar (1997)
Evidence for two nonidentical drug-interaction sites in the human P-glycoproteinProc Natl Acad Sci USA, 94
C Pascaud, M Garrigos, S Orlowski (1996)
Multidrug resistance transporter P-glycoprotein has distinct but interacting binding sites for cytotoxic drugs and reversing agentsBiochem J, 333
SK Choudhuri (2005)
Indian patent entitled “non toxic anti cancer drug resistance modifying agent and an anticancer kit including the same.” Classification no. A61K 31/00Bigpatents India, 1
SV Ambudkar, IH Lelong, J Zhang, CO Cardarelli, MM Gottesman, I Pastan (1992)
Partial purification and reconstitution of the human multidrug resistance pump: characterization of the drug-stimulatable ATP hydrolysisProc Natl Acad Sci USA, 89
N Maki, K Moitra, P Ghosh, S Dey (2006)
Allosteric modulation bypasses the requirement for ATP hydrolysis in regenerating low affinity transition state conformation of human P-glycoproteinJ Biol Chem, 281
C Martin, G Berridge, CF Higgins, P Mistry, P Charlton, R Callaghan (2000)
Communication between multiple drug binding sites on P-glycoproteinMol Pharmacol, 58
ZE Sauna, MM Smith, M Muller, SV Ambudkar (2001)
The mechanism of action of multidrug resistance-linked p-glycoproteinJ Bioenerg Biomembr, 33
Y Raviv, HB Pollard, EP Bruggemann, I Pastan, MM Gottesman (1990)
Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cellsJ Biol Chem, 265
F Tisato, C Marzano, M Porchia, M Pellei, C Santini (2009)
Copper in diseases and treatments, and copper-based anticancer strategiesMedcinal Res Rev, 1
S Majumder, P Dutta, A Mookerjee, SK Choudhuri (2006)
The role of a novel copper complex in overcoming doxorubicin resistance in Ehrlich ascites carcinoma cells in vivoChem Biol Interact, 159
MM Bradford (1976)
A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye bindingAnal Biochem, 72
A Garrigues, J Nugier, S Orlowski, E Ezan (2002)
A high-throughput screening microplate test for the interaction of drugs with P-glycoproteinAnal Biochem, 305
SG Aller, J Yu, A Ward, Y Weng, S Chittaboina, R Zhuo, PM Harrell, YT Trinh, Q Zhang, IL Urbatsch, G Chang (2009)
Structure of P-glycoprotein reveals a molecular basis for poly-specific drug bindingScience, 323
A Mookerjee, JM Basu, S Majumder, S Chatterjee, GS Panda, P Dutta, S Pal, P Mukherjee, T Efferth, S Roy, SK Choudhuri (2006)
A novel copper complex induces ROS generation in doxorubicin resistant Ehrlich ascitis carcinoma cells and increases activity of antioxidant enzymes in vital organs in vivoBMC Cancer, 6
MJ Kuffei, MM Ames (1995)
Comparative resistance of idarubicin, doxorubicin and their C-13 alcohol metaboUtes in human MDR1 transfected NIH-3T3 CellsCancer Chemother Pharmacol, 36
A Sandler, M Gordon, DP Alwis, I Pouliquen, L Green, P Marder (2004)
A phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancyClin Cancer Res, 10
JA Ludwig, G Szakacs, SE Martin, BF Chu (2006)
Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancerCancer Res, 66
CK Wan, GY Zhu, XL Shen, A Chattopadhyay, S Dey, WF Fong (2006)
Gomisin A alters substrate interaction and reverses P-glycoprotein-mediated multidrug resistance in GHepG2-DR cellsBiochem Pharmacol, 72
N Maki, P Hafkemeyer, S Dey (2003)
Allosteric modulation of human P-glycoprotein Inhibition of transport by preventing substrate translocation and dissociationJ Biol Chem, 278
G Rappa, A Lorico, MC Liu, GD Kruh, AH Cory, JG Cory, AC Sartorelli (1997)
Overexpression of the multidrug resistance genes mdr1, mdr3, and mrp in L1210 leukemia cells resistant to inhibitors of ribonucleotide reductaseBiochem Pharmacol, 54
AW Tolcher, KH Cowan, D Solomon, F Ognibene, B Goldspiel, R Chang (1996)
Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancerJ Clin Oncol, 14
BI Sikic (1999)
Modulation of multidrug resistance: a paradigm for translational clinical researchOncology (Huntingt), 3
SV Ambudkar, S Dey, CA Hrycyna, M Ramachandra, I Pastan, MM Gottesman (1999)
Biochemical, cellular and pharmacological aspects of the multidrug transporterAnnu Rev Pharmacol Toxicol, 39
G Szakacs, JK Paterson, JA Ludwig, C Booth-Genthe, MM Gottesman (2006)
Targeting multidrug resistance in cancerNat Rev Drug Discov, 5
DJ Boote, IF Dennis, PR Twentyman, RJ Osborne, C Laburte, S Hensel (1996)
Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancerJ Clin Oncol, 14
MM Gottesman, SV Ambudkar, D Xia (2009)
Structure of a multidrug transporter (News and Views article)Nat Biotech, 27
S Majumder, GS Panda, SK Choudhuri (2003)
Synthesis, characterization and biological properties of a novel copper complexEur J Med Chem, 38
One of the major reasons for multidrug resistance (MDR) in cancer is the overexpression of P-glycoprotein (P-gp, ABCB1), a drug efflux pump. A novel copper complex, namely, copper (II) N-(2-hydroxyacetophenone) glycinate (CuNG) previously synthesized and characterized by the authors had been tested in this study. In a cell-based assay system with human MDR1 cDNA overexpressed mouse fibroblast NIH MDR1-G185 cell line, we demonstrated that this metal complex can directly interact with this transporter. As CuNG increased cellular accumulation of doxorubicin in P-gp-expressing cells, we presumed that of CuNG may be potential to reverse P-gp-mediated drug resistance probably by lowering the P-gp expression at the protein as well as mRNA level. Interestingly, our studies on UIC2 (a conformation sensitive monoclonal antibody) binding assay indicated the direct interaction of CuNG with P-gp. However, CuNG did not compete for the substrate binding as photoaffinity labeling of P-gp with a substrate analog [125I] iodoarylazidoprazosin ([125I] IAAP) showed approximately twofold increase in [125I] IAAP binding in presence of CuNG. In vitro study showed that CuNG significantly stimulated P-gp-specific ATPase activity in isolated membrane preparations from NIH MDR1-G185 cells. This result further confirmed the CuNG–P-gp direct interaction. This study also demonstrated that CuNG has a drug interaction site different from verapamil-, vinblastine- and progesterone-binding sites on P-gp. Taken together, this is the first report of molecular interaction of any Schiff’s base metal chelate CuNG with human P-gp. This information may be useful to design more efficacious nontoxic metal-based drugs as MDR-reversing agents.
Molecular and Cellular Biochemistry – Springer Journals
Published: Jan 19, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.